|1.||Warkentin, Theodore E: 13 articles (01/2011 - 09/2002)|
|2.||de Boer, Anthonius: 8 articles (07/2015 - 04/2007)|
|3.||Supuran, Claudiu T: 6 articles (04/2014 - 08/2010)|
|4.||Rosendaal, Frits R: 6 articles (07/2010 - 04/2002)|
|5.||Iranshahi, Mehrdad: 5 articles (03/2014 - 01/2008)|
|6.||Verhoef, Talitha I: 4 articles (07/2015 - 07/2010)|
|7.||Li, Hongyan: 4 articles (01/2014 - 02/2010)|
|8.||Dai, Yue: 4 articles (12/2013 - 07/2009)|
|9.||Chen, Xiaoguang: 4 articles (01/2013 - 02/2010)|
|10.||Boujedaini, Naoual: 4 articles (06/2011 - 07/2009)|
|1.||Lymphedema (Milroy Disease)
03/01/1999 - "In both groups, the volume of arm lymphedema decreased (14.9% in Group A and 13.2% in Group B) (N.S.), the overall clinical score improved (12.9 +/- 4.3 to 5.7 +/- 3.5 in Group A and from 11.7 +/- 3.7 to 4.7 +/- 3.9 in Group B) (N.S.), and the overall efficacy of coumarin was similarly good or excellent (71.9% in Group A and 68.6% in Group B) (N.S.). "
01/01/1990 - "A randomized double blind study versus placebo has confirmed the occurrence of significant improvement of these mild swelling cases, and recommend the use of coumarin as supplemental therapy in mild lymphedema."
01/01/2005 - "However, it seems without doubt that the majority of studies conducted thus far suggest that coumarin (and other benzopyrones, i.e., the ruto-sides, which do not have hepatotoxic effects and which are often discussed in aggregate with coumarin) is effective in treating lymphedema, particularly when used in conjunction with complex physical therapy. "
02/04/1999 - "Coumarin has been reported to be effective for the treatment of women with lymphedema; we undertook a study in which we attempted to replicate those findings. "
09/01/1996 - "A study was performed on the use of an ideal phlebolymphological association (Tonka Beans, Gingko Biloba, Melilotus Officinalis) as a practical standpoint in the treatment of lymphedema of lower limbs in order to create an efficacious dose of Coumarin, Benzopyrones and Ginkolidi. "
11/27/1986 - "We conclude that in the second and third trimesters of pregnancy, coumarin derivatives provide effective protection against thromboembolism while causing few fetopathic effects, but that these agents are contraindicated from the 6th to the 12th weeks of gestation. "
05/01/1998 - "This study was performed to evaluate the incidence of thromboembolism as well as the benefit and risk of its prophylaxis with coumarin in this patient selection. "
11/01/2010 - "Thromboembolism and coumarin overdosage in a 19-year-old female: impact of pharmacogenetics."
11/01/2006 - "As the coumarin therapy didn't need to be discontinued some days before the surgical operation, so the days of hospital stay were reduced and there wasn't the risk of thromboembolism. "
05/01/1998 - "The prophylaxis of thromboembolism in gynecologic oncology with coumarin seems to be effective, safe and inexpensive."
05/15/2008 - "In addition, coumarin has a delayed onset of action, interacts with many medications, has a narrow therapeutic window, and is paradoxically prothrombotic in certain settings (ie, can precipitate "coumarin necrosis"). "
03/01/2014 - "Extensive coumarin-induced necrosis - a vasculopathy following oral anticoagulation."
04/25/2012 - "After consideration of the differential diagnoses and due to the typical clinical picture we made the diagnosis of coumarin necrosis. "
07/01/2010 - "We report the case of a 55-year-old female who presented with coumarin-induced skin necrosis affecting the right breast and the right deltoid area."
07/01/2010 - "Early lesions can be reversible with the discontinuation of anticoagulant therapy, but skin necrosis can reoccur even without any other coumarin based treatment. "
01/01/2016 - "The objective of this study is to investigate natural and synthetic coumarin derivatives with considerable anticancer capacity against three human cancer cell lines. "
08/28/2015 - "This is the first standalone review that emphasis on the assorted retrosynthetic approaches, important targets for molecularly targeted cancer therapy and structure activity relationship studies that highlight the chemical groups responsible for evoking the anticancer potential of coumarin derivatives reported from 2011 to 2014. "
01/01/2015 - "The present review is an attempt to study various coumarin derivatives of natural as well as synthetic origins, which are identified or developed for the treatment of different types of cancers. "
01/01/2014 - "This coumarin can be considered for further studies to reveal its exact mechanism of action and also its anti-cancer effects in vivo."
04/01/2012 - "A novel micelle of coumarin derivative monoend-functionalized PEG for anti-tumor drug delivery: in vitro and in vivo study."
01/01/2011 - "Age and coumarin-type anticoagulation are associated with the occurrence of intraplaque hemorrhage, while statins are associated less with intraplaque hemorrhage: a large histopathological study in carotid and femoral plaques."
01/01/2010 - "From 1999 to 2004 a number of observational studies firmly established associations between being carrier of the CYP2C9*2 and especially the CYP2C9*3 allele and reduced coumarin dose requirements and increased risks of overanticoagulation and even major bleeding compared to CYP2C9 wild type patients. "
02/01/2008 - "All patients were followed up until end of last coumarin treatment, hospitalization for bleeding, death, or end of study period. "
07/01/2004 - "It was, therefore, our objective to study the effect of the CYP2C9 polymorphisms on bleeding complications during initiation and maintenance phases of coumarin anticoagulant therapy. "
08/01/2003 - "Different definitions of major hemorrhage, INR target ranges, age distribution, burden of comorbid illness, and type of coumarin challenge comparability of studies. "
|4.||Aspirin (Acetylsalicylic Acid)
|9.||8-chlorocarbochromen (AD 6)
|1.||Prostheses and Implants (Prosthesis)
|4.||Vena Cava Filters (Inferior Vena Cava Filter)
|5.||Induced Abortion (Induced Abortions)